Table 1 Baseline characteristics of the patients
Characteristics | TACE plus apatinib plus camrelizumab (n = 80) | early combination group (n = 45) | late combination group (n = 35) |
|---|---|---|---|
Age (years), median (IQR) | 52 (46–62) | 53 (48–60) | 50 (43–63) |
Age group (years) | |||
  < 65 | 66 (82.5) | 37 (82.2) | 29 (82.9) |
  ≥ 65 | 14 (17.5) | 8 (17.8) | 6 (17.1) |
Sex | |||
 Male | 66 (82.5) | 36 (80.0) | 30 (85.7) |
 Female | 14 (17.5) | 9 (20.0) | 5 (14.3) |
ECOG PS | |||
 0 | 34 (42.5) | 15 (33.3) | 19 (54.3) |
 1 | 46 (57.5) | 30 (66.7) | 16 (45.7) |
Child–Pugh class | |||
 A | 58 (72.5) | 29 (64.4) | 29 (82.9) |
 B | 22 (27.5) | 16 (35.6) | 6 (17.1) |
Co-treatment time | |||
 Early combination | 45 (56.3) | 45 (100.0) | 0 (0.0) |
 Late combination | 35 (43.8) | 0 (0.0) | 35 (100.0) |
Extrahepatic metastases | 44 (55.0) | 27 (60.0) | 17 (48.6) |
Macrovascular invasion | 47 (58.8) | 30 (66.7) | 17 (48.6) |
BCLC stage | |||
 B | 13 (16.3) | 4 (8.9) | 9 (25.7) |
 C | 67 (83.7) | 41 (91.1) | 26 (74.3) |
Liver Cirrhosis | 70 (87.5) | 38 (84.4) | 32 (91.4) |
Hepatitis B | 65 (81.3) | 35 (77.8) | 30 (85.7) |
Tumor distribution | |||
 Single | 13 (16.3) | 7 (15.6) | 6 (17.1) |
 Multiple | 67 (83.8) | 38 (84.4) | 29 (82.9) |
 Tumor size (cm, mean ± SD) | 9.7 ± 4.7 | 10.0 ± 4.5 | 9.3 ± 5.0 |
  < 10 cm | 45 (56.3) | 25 (55.6) | 20 (57.1) |
  ≥ 10 cm | 35 (43.8) | 20 (44.4) | 15 (42.9) |
Laboratory parameters | |||
 RBC (10^9/L, mean ± SD) | 4.1 ± 0.8 | 4.0 ± 0.8 | 4.2 ± 0.9 |
 Hb (g/L), median (IQR) | 128 (110–138) | 129 (112–136) | 128 (110–139) |
 Platelet (10^9/L), median (IQR) | 163 (119–228) | 151 (111–210) | 181 (144–372) |
 WBC (10^12/L, mean ± SD) | 5.8 ± 1.9 | 5.5 ± 1.8 | 6.3 ± 2.0 |
 Neutrophils (10^9/L, mean ± SD) | 3.9 ± 1.7 | 3.6 ± 1.4 | 4.2 ± 1.9 |
 Lymphocyte (10^9/L, mean ± SD) | 1.3 ± 0.5 | 1.2 ± 0.5 | 1.4 ± 0.5 |
 NLR, median (IQR) | 2.8 (2.0–4.5) | 2.9 (2.2–4.6) | 2.8 (1.8–4.4) |
 ALT (U/L), median (IQR) | 38 (25–57.5) | 38.5 (25–58) | 35 (25–56.5) |
 AST (U/L), median (IQR) | 46 (34.5–84.5) | 61.5 (39–105) | 41 (33.5–54) |
 TBIL (μmmol/L), median (IQR) | 14.4 (10.8–19) | 15.2 (10.8–21.7) | 13.4 (10.7–17.4) |
 ALP (U/L), median (IQR) | 134 (102–203.5) | 147 (109–224) | 118 (89.5–169.5) |
 TBA (μmol/L), median (IQR) | 7.8 (4.1–14.3) | 8.35 (4.1–17) | 7.7 (4.5–13.1) |
 ALB (g/L, mean ± SD) | 36.4 ± 4.9 | 35.2 ± 4.1 | 38.0 ± 5.3 |
AFP (ng/mL) | |||
  < 200 | 28 (35.0) | 14 (31.1) | 14 (12.3) |
  ≥ 200 | 52 (65.0) | 31 (68.9) | 21 (60.0) |